MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MorphoSys AG - American Depositary Shares (NQ:MOR)

18.96 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MorphoSys AG - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
MorphoSys AG: Financial Calendar 2023
Via ACCESSWIRE
MorphoSys Earnings Preview
 
Via Benzinga
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
Via ACCESSWIRE
Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
Via ACCESSWIRE
Why Adobe Shares Are Trading Higher; Here Are 31 Stocks Moving Premarket
Gainers Minim, Inc. (NASDAQ: MINM) shares rose 66.5% to $0.2903 in pre-market trading after gaining over 10% on Thursday. Minim, last month, reported worse-than-expected results. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting off the final trading day this week with a look at the biggest pre-market stock movers to watch for Friday! 
Via InvestorPlace
Guardant Health, Novavax And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
MorphoSys Highlights Preliminary Data From Tulmimetostat Study Across Broad Array of Advanced Tumors
 
Via Benzinga
MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs
 
Via Benzinga
Is The Oil And Gas Bull Market Over? This 2X Leveraged ETF Inversely Tracks Exxon, Occidental And More
The Direxion Daily S&P Oil & Gas Exp & Prod Bear 2X Shares (NYSE: DRIP) was surging Monday after the Group of Seven (G7) nations and the European Union agreed to put a price cap of 
Via Benzinga
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
From MorphoSys AG
Via Business Wire
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday saw 33 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Earnings Scheduled For November 16, 2022
Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is estimated to report earnings for its third quarter. 
Via Benzinga
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target. 
Via Benzinga
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map. 
Via Investor's Business Daily
Facebook Stalls Portal & Smartwatch Projects, Visa Breaks Debit Card Tie Up With FTX, $3B Bitcoin Withdrawn From Crypto Exchanges: Top Stories Monday, Nov. 14
Reuters 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back and get ready for the week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday morning! 
Via InvestorPlace
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
 
Via Benzinga
Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus
The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark... 
Via Benzinga
Why MorphoSys Shares Are Trading Lower By Around 32%; Here Are 30 Stocks Moving Premarket
    
Via Benzinga
MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
Via ACCESSWIRE
MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
Via ACCESSWIRE
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story